Infinity, AZ halt prostate cancer trial

Infinity Pharmaceuticals' shares fell on the news that it has halted a Phase II trial of IPI-504 for prostate cancer. The company, which partnered with MedImmune/AstraZeneca on the drug, said it has not observed evidence of biologic activity in the trial and has, therefore, concluded that the overall risk-benefit ratio does not justify continuing a signal-finding study as a single agent in this indication. Infinity is not abandoning the drug, however. The company is conducting trials of the drug for non-small cell lung cancer, gastrointestinal stromal tumors, and evaluating IPI-504 in combination with docetaxel.

"With our partners at AstraZeneca, we are pursuing a rigorous and broad clinical research program, including multiple early, disease-specific, signal-finding trials to determine which patients we believe are most likely to benefit from our novel anti-chaperone agent," said Julian Adams, Ph.D., president of research and development and chief scientific officer at Infinity. "We remain committed to the clinical development of IPI-504 in GIST and non-small cell lung cancer, where we have seen early evidence of activity, as well as to future studies in additional tumor types."

- check out Inifinity's release for more

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.